Highly actve antirretroviral therapy responce in patients over 50 years old living with HIV/AIDS infection

For the year 2015 >50% of the population living with the human immunodeficiency virus infection will be >50 years old, facing it diverse challenges in their attention. In the current study the objetive to assess the response to the highly active antiretroviral therapy (HAART), epidemiological and clinical characteristics in patients with human immnodeficiency virus infection/acquired immunodeficiency syndrome >50 years old, was proposed. A descriptive, retrospective, observational, non-experimental, cases and control desing study (patients >50 years old, cases; and <50 years old, controls), comparing their basal, at 6 months and t 12 months evalutions, between january 2005 and june 2009, was done. A total 311 patients, 99 cases (>50 years old) and 212 controls (<50 years old) were included. Females represented a third of the population. More than 65% of the patients consulted in advanced stages of diseases, 47% corresponded with acquired immnodeficiency syndrome stage C3. Mean time between diagnosis and beginning of highly active antiretroviral therapy was >1 year, in both groups. Most used highly active antiretroviral therapy schemes were AZT/3TC/EFV and AZT/3TC+LOP/RIT. No significant differences between immunological and virological responce to highly active antiretroviral therapy at 6 and 12 months between both groups were found; mean values of viral load at 6 months: 5,821.08 RNA copies/mm³ (2.21 log) and 6,081.92 RNA copies/mm³ (2.28 log) for mayor adults and young patients, respectively. In mayor adults, increase in mean values of TCD4 + lymphocyte counts post-highly active antiretroviral therapy were significant (P<0.05) when compared basal with 12 months moments. In young patients that significant change was reached at 6 months. More than 85% of the patients had undetectable viral at 12 months. In patients >50 years old a good immunological and virological responce was observed, being similar to that seen in young patients, at 6 and 12 months.....